| The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients : A Physiologically Based Pharmacokinetic Modeling Study | Clinical pharmacology and therapeutics |  | | 2025 | 77 | 504 |
|
| Assessing the intrinsic and extrinsic factors of pharmacokinetic variability for precision medicine: A focus on CYP2C19 and the influence of genetic polymorphisms on drug interactions | |  | | 2024 | 360 | 14 |
|
| Stereoselective separation of omeprazole and 5-hydroxy-omeprazole using dried plasma spots and a heart-cutting 2D-LC approach for accurate CYP2C19 phenotyping | Journal of chromatography. B | | | 2024 | 112 | 130 |
|
| Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia | JAMA | | | 2022 | 174 | 0 |
|
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | | | 2022 | 160 | 194 |
|
| Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends | Frontiers in pharmacology | | | 2021 | 188 | 424 |
|
